Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

Abstract

These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. (Funded by the World Health Organization; ISRCTN Registry number, ISRCTN83971151; ClinicalTrials.gov number, NCT04315948.).

Keywords

Coronavirus disease 2019 (COVID-19)InterimSolidarity2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyMedicinePolitical scienceInternal medicineLawOutbreak

MeSH Terms

Adenosine MonophosphateAgedAlanineAntiviral AgentsCOVID-19Drug TherapyCombinationFemaleHospital MortalityHospitalizationHumansHydroxychloroquineIntention to Treat AnalysisInterferon beta-1aKaplan-Meier EstimateLength of StayLopinavirMaleMiddle AgedRespirationArtificialTreatment FailureCOVID-19 Drug Treatment

Affiliated Institutions

Related Publications

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Peter Horby , Marion Mafham , Louise Linsell +26 more

BACKGROUND: Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrol...

2020 New England Journal of Medicine 1266 citations

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Timothy P. Sheahan , Amy Sims , Sarah R. Leist +16 more

Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease associated with more than 2468 human infections and over 851 death...

2020 Nature Communications 1785 citations

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Jia Liu , Ruiyuan Cao , Mingyue Xu +7 more

Dear Editor, The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) poses a serious threat to g...

2020 Cell Discovery 2168 citations

Remdesivir for the Treatment of Covid-19 — Final Report

John H. Beigel , Kay M Tomashek , Lori E. Dodd +37 more

Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory trac...

2020 New England Journal of Medicine 7559 citations

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman , David Chien Lye , David S.C. Hui +23 more

In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. ...

2020 New England Journal of Medicine 1419 citations

Publication Info

Year: 2020
Type: article
Volume: 384
Issue: 6
Pages: 497-511
Citations: 2570
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2570

OpenAlex

Influential

1872

CrossRef

Cite This

APA Style

                            
                                
                                    Hongchao Pan, 
                                
                                    Richárd Pető, 
                                
                                    Ana‐Maria Henao‐Restrepo
                                
                                et al.
                            
                            (2020). 
                            Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. 
                            New England Journal of Medicine
                            , 384
                            (6)
                            , 497-511.
                            https://doi.org/10.1056/nejmoa2023184
                        

Identifiers

DOI: 10.1056/nejmoa2023184
PMID: 33264556
PMCID: PMC7727327

Data Quality

Data completeness: 90%